Intra-Cellular Therapies Cost of Revenue 2011-2025 | ITCI

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Quarterly Cost of Revenue Intra-Cellular Therapies

2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	69 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
69 K	69 K	69 K

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
Aclaris Therapeutics ACRS	2.79 M	$ 3.2	-1.69 %	$ 247 M	USA
Aptevo Therapeutics APVO	19.9 M	$ 1.07	-5.75 %	$ 295 K	USA
Ascendis Pharma A/S ASND	3.52 M	$ 213.33	-3.22 %	$ 5 B	Danmark
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
BioVie BIVI	312 K	$ 1.42	-1.85 %	$ 2.1 M	USA
Acasti Pharma ACST	76 K	-	4.01 %	$ 150 M	Canada
BioNTech SE BNTX	2.91 B	$ 93.93	-0.93 %	$ 27.2 B	Germany
Albireo Pharma ALBO	1.36 M	-	-0.23 %	$ 916 M	USA
Ampio Pharmaceuticals AMPE	369 K	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	358 M	$ 26.45	4.67 %	$ 1.28 B	USA
Anika Therapeutics ANIK	63.6 M	$ 9.6	0.37 %	$ 141 M	USA
Catalyst Biosciences CBIO	4.64 M	$ 12.98	-7.91 %	$ 854 M	USA
Axon Enterprise AXON	841 M	$ 548.58	-2.78 %	$ 41.6 B	USA
Ayala Pharmaceuticals AYLA	602 K	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	20.6 M	$ 2.37	2.83 %	$ 14.9 M	USA
AstraZeneca PLC AZN	12.4 B	$ 91.59	1.95 %	$ 96.9 B	Britain
Celldex Therapeutics CLDX	200 K	$ 27.09	-1.53 %	$ 1.74 M	USA
Acorda Therapeutics ACOR	15.3 M	-	-24.86 %	$ 820 K	USA
BeiGene, Ltd. BGNE	70.7 M	-	0.49 %	$ 251 B	Cayman-islands
Biohaven Pharmaceutical Holding Company Ltd. BHVN	91.7 M	$ 11.33	-1.78 %	$ 733 M	USA
Biogen BIIB	2.31 B	$ 175.2	0.63 %	$ 25.5 B	USA
Corcept Therapeutics Incorporated CORT	10.9 M	$ 87.67	-0.36 %	$ 9.05 B	USA
ADiTx Therapeutics ADTX	627 K	$ 1.43	-36.18 %	$ 18.8 K	USA
Bellicum Pharmaceuticals BLCM	436 K	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	24.8 M	-	-7.31 %	$ 87 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Catalyst Pharmaceuticals CPRX	68.8 M	$ 24.29	2.84 %	$ 2.88 B	USA